GlassScriptPhysician profile
James R Kee
NPI 1902340318
$26,944.94
in general payments reported to CMS, 2019-2025
15 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.80 · 2022: $23K · 2023: $3,267 · 2024: $301 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,700 · Food and Beverage: $1,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,700.00 |
| Food and Beverage | $1,045.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $20,000.00 | 2022 | |
| Smith+Nephew, INC. | $5,540.69 | 2022-2024 | Redapt, Real Intelligence, Aetos Shoulder System |
| Cgg Medical INC | $867.84 | 2022-2023 | |
| Stryker Corporation | $135.55 | 2024-2025 | Mako, Triathlon, Pangea |
| Vericel Corporation | $123.92 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $60.98 | 2025 | |
| Heron Therapeutics, INC. | $50.85 | 2024 | Zynrelef |
| Djo, LLC | $48.64 | 2024 | Cmf |
| Polynovo North America LLC | $19.48 | 2024 | Novosorb Btm |
| Organogenesis INC. | $19.12 | 2025 | Cygnus Dual |
| Midsouth Orthopedics INC. | $18.68 | 2023 | |
| Solventum Corporation | $17.93 | 2024 | Prevena, V.A.C. Veraflo Cleanse Choice |
| Depuy Synthes Sales INC. | $15.26 | 2024 | |
| Orthalign INC | $15.20 | 2023 | Orthalign Plus |
| Eisai INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Kee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.